Scholarlink

This is a case with metastatic melanoma who developed insulin dependent T1DM with DKA upon treatment of epacadostat and durvalumab in the context of pre-existing T2DM. The patient concluded cancer therapy with continued insulin requirement to maintain a stable hemoglobin A1c around 8%. He has since remained without recurrence of cutaneous disease until the last follow up for 7 years after pancreatic endocrine toxicity event.

错误：搜索内容不能为空，请输入英文关键词
错误：关键词超出字数限制，请精简
高级检索

Worsening Hyperglycemia During Immune Checkpoint Inhibitor Therapy

  • 章节

  • 发表日期：

    2025年

查看全文
  • Irene J. Lee,
  • Kei Takigawa,
  • Conor Best

摘要

This is a case with metastatic melanoma who developed insulin dependent T1DM with DKA upon treatment of epacadostat and durvalumab in the context of pre-existing T2DM. The patient concluded cancer therapy with continued insulin requirement to maintain a stable hemoglobin A1c around 8%. He has since remained without recurrence of cutaneous disease until the last follow up for 7 years after pancreatic endocrine toxicity event.